- The concussion controversy surrounding Tua Tagovailoa has prompted both the NFL and the NFLPA to revisit the league’s concussion protocol in a move designed to enhance player safety
- In the wake of this controversy, Odyssey is emphasizing the potential value of its PRV-002 novel compound for the treatment of concussions and the benefit of the players
- According to a report published by Vox, there are approximately 0.41 concussions per NFL game in American football, with 9.3% of concussions involving the loss of consciousness and 2.4% resulting in hospitalizations
- With such cases, there is a need to revise the NFL’s concussion protocol and push for a treatment option that is effective in the treatment of this condition
- Odyssey is at the forefront of a possible pharmaceutical treatment option, as it advances its clinical trials, to potentially receive FDA approval
Odyssey Health (OTC: ODYY) is looking to push its PRV-002 novel compound for the treatment of concussions given the National Football League (“NFL”) and National Football League Players Association’s (“NFLPA”) joint announcement on changes to the league’s concussion protocol (https://ibn.fm/LOjTi).
As a medical technology company focused on developing lifesaving medical products that offer technological and clinical advantages over current standards of care, Odyssey recognizes the severity of concussions, especially in the NFL. In addition, it acknowledges the ineffectiveness of current treatment options available for patients.
The Tua Tagovailoa concussion controversy has prompted the NLF and the NFLPA to revisit the league’s concussion protocol, citing a dire need to “enhance player safety.” On September 25, Tagovailoa was checked for a concussion, but the neurotrauma consultant responsible for the check made “several mistakes” in his evaluation, according to multiple reports.
The Dolphins quarterback sustained a hit in the Week 3 game, but the team reported that he passed concussion protocols. On Thursday, September 29, he suffered another injury following a similar tackle, leaving him with head and neck injuries, coupled with a confirmed concussion which resulted in a trip to the hospital.
The injuries following the second incident raised significant concerns and backlash, with many arguing that Tagovailoa should not have played and was in danger of serious injury. This led to the launch of an investigation, which is still ongoing. It has so far led to the termination of the neurotrauma consultant who checked Tagovailoa on September 25.
On September 28, Odyssey announced the completion of all cohorts for its Phase I Single Ascending Dosing (“SAD”) and Multiple Ascending Dosing (“MAD”) clinical trial for its PRV-002 novel compound for concussion treatment. The drug proved safe and well tolerated throughout the trial, paving the way for the next phase of its clinical trial (https://ibn.fm/1puyq).
PRV-002 has been shown to significantly improve both neuroscore and memory score following injury in rats subjected to concussion models. While it is yet to receive approval from the United States Food and Drug Administration (“FDA”), this compound has shown significant potential in pre-clinical studies treating concussions, going above and beyond what current alternatives in the market offer.
A 2020 report published by Vox noted that American football has approximately 0.41 concussions per NFL game. The study also pointed out that 9.3% of concussions involve loss of consciousness, and 2.4% result in hospitalizations (https://ibn.fm/DAFZE). With such cases, there is a need to revise the NFL’s concussion protocol to guarantee the safety of players. There is also an urgency to push for a treatment option that effectively treats the condition.
Odyssey is at the forefront of pushing a novel treatment as it advances its clinical trials with the ultimate objective of receiving FDA approval.
For more information, visit the company’s website at www.OdysseyHealthInc.com.
NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.